drugset / Trial / NCT00631449
Raltegravir Intensification in HIV-infected Patients
Phase 4
Completed
30 enrolled
University of California, San Francisco
Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether treatment with Raltegravir further decreases HIV viral replication in HAART-suppressed, HIV-infected patients, potentially improving immune response to antiretroviral therapy.
Timeline
- Start
- 2008-02
- Primary completion
- 2009-09
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Raltegravir | Other / unclassified | 400 mg | Oral |